Eli Lilly reported positive Phase III data for orforglipron, an oral GLP-1 receptor agonist, in adults with obesity and type 2 diabetes. All doses met primary and key secondary endpoints, producing significant weight loss—up to 10.5% at the highest dose—and improvements in glycemic control and cardiometabolic risk factors over 72 weeks. Despite promising efficacy, the drug exhibited higher discontinuation rates due to side effects compared to injectables, raising questions over tolerability. Lilly plans to submit for regulatory approval imminently, entering a competitive market against established GLP-1 agents.